Stay updated with breaking news from Eha congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Single-agent IBI322 elicited responses with favorable safety in patients with classical Hodgkin lymphoma that had become resistant to anti–PD-1/PD-L1 therapy, according to data from a phase 1 trial. ....
Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis. ....
Mohamad Mohty, MD, PhD, discusses extended follow-up from cohort A of the phase 2 MagnetisMM-3 trial of elranatamab in patients with relapsed/refractory multiple myeloma. ....
Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. ....
Harry Gill, MD, FRCP, FRCPath, discusses the investigation of an all-oral combination of arsenic trioxide, all trans retinoic acid, and ascorbic acid in patients with newly diagnosed acute promyelocytic leukemia. ....